Detalhe da pesquisa
1.
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.
Cancer
; 129(5): 714-727, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36597662
2.
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Lancet Oncol
; 21(12): 1589-1601, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125909
3.
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Cancer
; 126(2): 373-380, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769875
4.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(7): 629-640, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959700
5.
De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.
FASEB J
; : fj201800204, 2018 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29906244
6.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923550
7.
Master protocols in lung cancer: experience from Lung Master Protocol.
Curr Opin Oncol
; 30(2): 92-97, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29329112
8.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol
; 17(11): 1497-1508, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27745820
9.
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.
J Transl Med
; 14(1): 295, 2016 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27756323
10.
Osimertinib in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(20): 1993-4, 2017 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28514610
11.
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Invest New Drugs
; 32(1): 123-34, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23579358
12.
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.
Nat Commun
; 14(1): 1071, 2023 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849516
13.
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
J Thorac Oncol
; 18(8): 1094-1102, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146752
14.
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.
JTO Clin Res Rep
; 4(3): 100423, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36925644
15.
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
J Natl Cancer Inst
; 115(4): 437-446, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36625510
16.
Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia.
Cancer Med
; 12(6): 7508-7518, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36721313
17.
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Clin Cancer Res
; 29(17): 3340-3351, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379430
18.
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(1): 72-81, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34782240
19.
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
J Clin Oncol
; 40(21): 2295-2306, 2022 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658002
20.
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Nat Commun
; 13(1): 1797, 2022 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379845